ByTrending Posts
Is AstraZeneca Building the Most Diversified Growth Engine…
Late January–Early February 2026 | Full-Year 2025 Earnings Preview | Oncology, CVRM & Platform Innovation AstraZeneca is expected…
Can Merck Redefine Its Growth Story Beyond Keytruda…
Late January 2026 | Full-Year 2025 Earnings Preview | Oncology, Vaccines & Post-Keytruda Strategy Merck & Co. (known…
Can Novo Nordisk Defend Its Obesity Crown as…
Late January 2026 | Full-Year 2025 Earnings Preview | Obesity & Metabolic Disease Strategy Novo Nordisk is set…
Will Eli Lilly’s 2025 Earnings Prove That AI…
Late January 2026 | Full-Year 2025 Earnings Preview | AI-Driven Biopharma Leadership Eli Lilly is set to report…
Will Sanofi’s 2025 Earnings Cement Dupixent’s Leadership—and Its…
Late January 2026 | Full-Year 2025 Earnings Preview | Immunology & Dermatology Focus Sanofi is set to report…
Can AbbVie’s 2025 Earnings Prove Its Post-Humira Portfolio…
Late January 2026 | Full-Year 2025 Earnings Preview | Biopharma Growth Strategy AbbVie is set to report its…
Will Johnson & Johnson’s 2025 Earnings Reinforce Confidence…
Late January 2026 | Full-Year 2025 Earnings Preview | Diversified Pharma Outlook Johnson & Johnson (J&J) is set…
Can Pfizer’s 2025 Earnings Reignite Confidence in Its…
Late January 2026 | Full-Year 2025 Earnings Preview | Big Pharma Strategy Reset Pfizer is set to report…
Will Novartis’ January 2026 Earnings Validate the Strength…
January 30, 2026 | Full-Year 2025 Earnings Preview | Innovative Medicines Outlook Novartis is scheduled to report its…
Trending Posts
Latest Stories
VA’s Nationwide Ambient AI Scribe Rollout: Burnout Buster or Documentation Digitized Trap?
The U.S. Department of Veterans Affairs on March 4, 2026, greenlit ambient scribe AI from…
Gilead’s $8B Arcellx CAR-T Swoop & Lilly Zepbound Triumph: Obesity/CAR-T Mania or Bubble Burst Ahead?
Gilead’s March 2026 $8B acquisition of Arcellx—securing CAR-T anito-cel for multiple myeloma with 73% ORR…
FDA’s AZ/GSK Biologics Rejections: Data Integrity Wake-Up or R&D Overhaul Catalyst?
FDA rejection letters issued March 3-4, 2026, flagged data integrity lapses in AstraZeneca’s subcutaneous tezepelumab…
Acadia’s Daybue CHMP Fight: $2B Rett Revenue at Stake or EMA Brick Wall?
Acadia Pharmaceuticals on March 3, 2026, fired back at CHMP’s rejection of Daybue (trofinetide) expansion…
Gallery
